Quest Diagnostics (NYSE:DGX) Given New $236.00 Price Target at Robert W. Baird

Quest Diagnostics (NYSE:DGX) had its target price raised by investment analysts at Robert W. Baird from $232.00 to $236.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s price target suggests a potential upside of 13.68% from the stock’s current price.

A number of other equities analysts have also weighed in on DGX. Truist Financial lifted their price objective on Quest Diagnostics from $220.00 to $225.00 and gave the company a “hold” rating in a research note on Wednesday, April 22nd. Barclays boosted their price target on Quest Diagnostics from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Wednesday, April 22nd. UBS Group raised their price objective on shares of Quest Diagnostics from $210.00 to $220.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 22nd. Evercore set a $225.00 price target on shares of Quest Diagnostics in a report on Tuesday, April 21st. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $225.00 price objective on shares of Quest Diagnostics in a report on Tuesday, April 21st. Seven research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, Quest Diagnostics presently has a consensus rating of “Moderate Buy” and a consensus target price of $217.17.

Quest Diagnostics Stock Up 0.1%

NYSE:DGX opened at $207.60 on Monday. The company’s 50 day moving average is $198.87 and its two-hundred day moving average is $195.17. The company has a market cap of $22.98 billion, a PE ratio of 22.94, a P/E/G ratio of 2.47 and a beta of 0.58. Quest Diagnostics has a twelve month low of $164.65 and a twelve month high of $219.20. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.67.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.37 by $0.13. The company had revenue of $2.90 billion during the quarter, compared to analyst estimates of $2.83 billion. Quest Diagnostics had a return on equity of 15.60% and a net margin of 9.07%.The firm’s quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter last year, the business posted $1.94 EPS. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Analysts anticipate that Quest Diagnostics will post 10.72 EPS for the current year.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the sale, the senior vice president directly owned 13,510 shares in the company, valued at $2,702,000. This represents a 37.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the transaction, the chief executive officer owned 132,423 shares in the company, valued at $25,708,601.22. The trade was a 7.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Quest Diagnostics

Large investors have recently made changes to their positions in the stock. Norges Bank acquired a new position in Quest Diagnostics during the fourth quarter worth $229,522,000. Boston Partners increased its stake in shares of Quest Diagnostics by 32.8% in the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock worth $767,978,000 after acquiring an additional 997,033 shares during the last quarter. EdgePoint Investment Group Inc. increased its stake in shares of Quest Diagnostics by 95.5% in the 4th quarter. EdgePoint Investment Group Inc. now owns 1,661,072 shares of the medical research company’s stock worth $288,246,000 after acquiring an additional 811,320 shares during the last quarter. UBS Group AG raised its holdings in shares of Quest Diagnostics by 67.8% during the 4th quarter. UBS Group AG now owns 1,114,451 shares of the medical research company’s stock worth $193,391,000 after acquiring an additional 450,161 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of Quest Diagnostics by 36.3% during the 2nd quarter. Bank of America Corp DE now owns 1,599,602 shares of the medical research company’s stock worth $287,337,000 after acquiring an additional 426,399 shares during the period. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.